SK278896B6 - Použitie magnézium-pyridoxal-5'-fosfátglutaminátu - Google Patents

Použitie magnézium-pyridoxal-5'-fosfátglutaminátu Download PDF

Info

Publication number: SK278896B6
Authority: SK; Slovakia
Prior art keywords: ldl; cholesterol; mppg; pyridoxal; preparation
Prior art date: 1990-05-25

Application number

SK1563-91A

Other languages

English (en)

Slovak (sk)

Inventor

Werner Schneider

Britta Meyer

Erich F. Elstner

Original Assignee

Steigerwald Arzneimittelwerk Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-25

Filing date

1991-05-24

Publication date

1998-04-08

1991-05-24 Application filed by Steigerwald Arzneimittelwerk Gmbh filed Critical Steigerwald Arzneimittelwerk Gmbh

1998-04-08 Publication of SK278896B6 publication Critical patent/SK278896B6/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims description 6
229940079593 drug Drugs 0.000 title abstract description 5
239000013543 active substance Substances 0.000 title 1
150000002978 peroxides Chemical class 0.000 claims abstract description 19
208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 12
108010007622 LDL Lipoproteins Proteins 0.000 claims description 20
102000007330 LDL Lipoproteins Human genes 0.000 claims description 20
208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
206010003210 Arteriosclerosis Diseases 0.000 claims description 7
208000019553 vascular disease Diseases 0.000 claims description 7
238000011321 prophylaxis Methods 0.000 claims description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
229910052749 magnesium Inorganic materials 0.000 claims description 4
239000011777 magnesium Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
230000001565 angiopathic effect Effects 0.000 claims description 2
238000011282 treatment Methods 0.000 abstract description 7
ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 abstract description 3
150000001875 compounds Chemical class 0.000 abstract description 2
MGNJVOVHTIAIQY-UHFFFAOYSA-L magnesium;(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl phosphate Chemical compound [Mg+2].CC1=NC=C(COP([O-])([O-])=O)C(C=O)=C1O MGNJVOVHTIAIQY-UHFFFAOYSA-L 0.000 abstract description 2
230000002792 vascular Effects 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 48
235000012000 cholesterol Nutrition 0.000 description 18
PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 13
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 11
208000029078 coronary artery disease Diseases 0.000 description 11
235000005911 diet Nutrition 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
230000037213 diet Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 8
235000014113 dietary fatty acids Nutrition 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 6
FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
150000003626 triacylglycerols Chemical class 0.000 description 5
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
239000005977 Ethylene Substances 0.000 description 4
206010033307 Overweight Diseases 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
208000006575 hypertriglyceridemia Diseases 0.000 description 4
208000030159 metabolic disease Diseases 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 3
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
235000020778 linoleic acid Nutrition 0.000 description 3
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
-1 lipid peroxide Chemical class 0.000 description 3
239000011572 manganese Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 3
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 3
229960001327 pyridoxal phosphate Drugs 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
230000036778 atheroma formation Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
238000011109 contamination Methods 0.000 description 2
RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003999 initiator Substances 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
230000035882 stress Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000013544 Platelet disease Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
229940099352 cholate Drugs 0.000 description 1
TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229940083759 high-ceiling diuretics aryloxyacetic acid derivative Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000003516 hyperlipidaemic effect Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
WHOMFKWHIQZTHY-UHFFFAOYSA-N pyridoxine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-N 0.000 description 1
150000003227 pyridoxines Chemical class 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1563-91A 1990-05-25 1991-05-24 Použitie magnézium-pyridoxal-5'-fosfátglutaminátu SK278896B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4016963A DE4016963A1 (de)	1990-05-25	1990-05-25	Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben

Publications (1)

Publication Number	Publication Date
SK278896B6 true SK278896B6 (sk)	1998-04-08

Family

ID=6407228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1563-91A SK278896B6 (sk)	1990-05-25	1991-05-24	Použitie magnézium-pyridoxal-5'-fosfátglutaminátu

Country Status (28)

Country	Link
US (1)	US5372999A (de)
EP (1)	EP0458287B1 (de)
JP (1)	JPH07119174B2 (de)
KR (1)	KR970005180B1 (de)
CN (1)	CN1050750C (de)
AT (1)	ATE142884T1 (de)
AU (1)	AU651108B2 (de)
CA (1)	CA2043228C (de)
CZ (1)	CZ280683B6 (de)
DE (2)	DE4016963A1 (de)
DK (1)	DK0458287T3 (de)
EG (1)	EG19730A (de)
ES (1)	ES2091262T3 (de)
GR (1)	GR3021077T3 (de)
HR (1)	HRP931445B1 (de)
HU (1)	HU219223B (de)
IE (1)	IE76728B1 (de)
IL (1)	IL98156A (de)
IN (1)	IN173057B (de)
LT (1)	LT3335B (de)
LV (1)	LV10046B (de)
MD (1)	MD306C2 (de)
MX (1)	MX171883B (de)
RU (1)	RU2041713C1 (de)
SI (1)	SI9110925A (de)
SK (1)	SK278896B6 (de)
UA (1)	UA26973A1 (de)
ZA (1)	ZA913692B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19527820A1 (de) *	1995-07-28	1997-01-30	Leniger Follert Elfriede Prof	Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) *	1995-09-04	2000-04-20	Steigerwald Arzneimittelwerk	Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) *	1998-07-09	2000-03-28	Medicure Inc.	Treatment of cardiovascular and related pathologies
US6339085B1 (en)	1999-03-08	2002-01-15	The University Of Manitoba	Therapeutics for cardiovascular and related diseases
US6489345B1 (en)	1999-07-13	2002-12-03	Medicure, Inc.	Treatment of diabetes and related pathologies
EP1872797A3 (de) *	1999-08-24	2008-04-02	Medicure International Inc.	Behandlung kardiovaskulärer und verwandter Leiden
US7442689B2 (en) *	2000-02-29	2008-10-28	Medicure International Inc.	Cardioprotective phosphonates and malonates
AU3718501A (en)	2000-02-29	2001-09-12	Medicure Int Inc	Cardioprotective phosphonates and malonates
WO2001072309A2 (en)	2000-03-28	2001-10-04	Medicure International Inc.	Treatment of cerebrovascular disease
RU2163132C1 (ru) *	2000-06-01	2001-02-20	Научно-исследовательский центр традиционной фитотерапии	Способ лечения сердечно-сосудистых заболеваний фитопрепаратом и лекарственный сбор для лечения сердечно-сосудистых заболеваний
ATE364595T1 (de)	2000-07-07	2007-07-15	Medicure Int Inc	Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en)	2000-07-07	2005-05-24	Medicure International Inc.	Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en)	2001-07-06	2003-04-15	Medicure International Inc.	Pyridoxine and pyridoxal analogues: novel uses
US20070060549A1 (en) *	2004-08-10	2007-03-15	Friesen Albert D	Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006050598A1 (en)	2004-10-28	2006-05-18	Medicure International Inc.	Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en)	2004-10-28	2008-12-02	Medicure International, Inc.	Aryl sulfonic pyridoxines as antiplatelet agents
AU2008224883A1 (en)	2007-03-14	2008-09-18	Sierra Molecular Corporation	Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
RU2484843C1 (ru) *	2012-04-03	2013-06-20	Алексей Кириллович Пехтерев	Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE246172C (de)
DE2461742C2 (de) *	1974-12-28	1983-01-27	Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt	Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) *	1988-03-10	1989-09-21	Knoll Ag	Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

1990
- 1990-05-25 DE DE4016963A patent/DE4016963A1/de active Granted
1991
- 1991-05-13 IN IN362CA1991 patent/IN173057B/en unknown
- 1991-05-15 ZA ZA913692A patent/ZA913692B/xx unknown
- 1991-05-16 IL IL9815691A patent/IL98156A/en active IP Right Grant
- 1991-05-22 EG EG32091A patent/EG19730A/xx active
- 1991-05-22 AT AT91108217T patent/ATE142884T1/de not_active IP Right Cessation
- 1991-05-22 DK DK91108217.0T patent/DK0458287T3/da active
- 1991-05-22 KR KR1019910008233A patent/KR970005180B1/ko not_active Expired - Fee Related
- 1991-05-22 EP EP91108217A patent/EP0458287B1/de not_active Expired - Lifetime
- 1991-05-22 DE DE69122170T patent/DE69122170T2/de not_active Expired - Fee Related
- 1991-05-22 ES ES91108217T patent/ES2091262T3/es not_active Expired - Lifetime
- 1991-05-23 SI SI9110925A patent/SI9110925A/sl unknown
- 1991-05-24 MX MX025919A patent/MX171883B/es unknown
- 1991-05-24 HU HU756/91A patent/HU219223B/hu not_active IP Right Cessation
- 1991-05-24 RU SU914895539A patent/RU2041713C1/ru active
- 1991-05-24 IE IE178391A patent/IE76728B1/en not_active IP Right Cessation
- 1991-05-24 CZ CS911563A patent/CZ280683B6/cs not_active IP Right Cessation
- 1991-05-24 SK SK1563-91A patent/SK278896B6/sk unknown
- 1991-05-24 JP JP3149739A patent/JPH07119174B2/ja not_active Expired - Lifetime
- 1991-05-24 AU AU77301/91A patent/AU651108B2/en not_active Ceased
- 1991-05-24 UA UA4895539A patent/UA26973A1/uk unknown
- 1991-05-24 CA CA002043228A patent/CA2043228C/en not_active Expired - Fee Related
- 1991-05-25 CN CN91104365A patent/CN1050750C/zh not_active Expired - Fee Related
1993
- 1993-04-02 US US08/041,896 patent/US5372999A/en not_active Expired - Fee Related
- 1993-05-14 LV LVP-93-343A patent/LV10046B/en unknown
- 1993-05-31 LT LTIP580A patent/LT3335B/lt not_active IP Right Cessation
- 1993-11-26 HR HRP-925/91A patent/HRP931445B1/xx not_active IP Right Cessation
1994
- 1994-11-25 MD MD94-0391A patent/MD306C2/ro active IP Right Grant
1996
- 1996-09-19 GR GR960402156T patent/GR3021077T3/el unknown

Also Published As

Publication number	Publication date
HRP931445A2 (en)	1996-02-29
GR3021077T3 (en)	1996-12-31
CN1057391A (zh)	1992-01-01
CZ280683B6 (cs)	1996-04-17
JPH07119174B2 (ja)	1995-12-20
DE4016963A1 (de)	1991-11-28
CA2043228A1 (en)	1991-11-26
MD306C2 (ro)	1996-02-29
UA26973A1 (uk)	2000-02-28
KR910019616A (ko)	1991-12-19
IL98156A (en)	1996-06-18
JPH04235130A (ja)	1992-08-24
CA2043228C (en)	1998-07-14
EG19730A (en)	1996-01-31
IE911783A1 (en)	1991-12-04
SI9110925A (sl)	1998-06-30
MX171883B (es)	1993-11-22
IN173057B (de)	1994-02-05
DE69122170T2 (de)	1997-02-20
KR970005180B1 (ko)	1997-04-14
DE4016963C2 (de)	1992-04-30
IL98156A0 (en)	1992-06-21
DK0458287T3 (da)	1996-10-07
US5372999A (en)	1994-12-13
DE69122170D1 (de)	1996-10-24
LTIP580A (en)	1994-12-27
EP0458287B1 (de)	1996-09-18
RU2041713C1 (ru)	1995-08-20
AU651108B2 (en)	1994-07-14
IE76728B1 (en)	1997-11-05
CS156391A3 (en)	1992-02-19
EP0458287A2 (de)	1991-11-27
MD306B1 (ro)	1995-10-31
HU911756D0 (en)	1991-12-30
AU7730191A (en)	1991-11-28
ATE142884T1 (de)	1996-10-15
LV10046A (lv)	1994-05-10
HRP931445B1 (en)	2000-04-30
ZA913692B (en)	1992-02-26
CN1050750C (zh)	2000-03-29
HUT58204A (en)	1992-02-28
EP0458287A3 (en)	1992-04-08
LT3335B (en)	1995-07-25
LV10046B (en)	1995-02-20
ES2091262T3 (es)	1996-11-01
HU219223B (en)	2001-03-28

Publication	Publication Date	Title
SK278896B6 (sk)	1998-04-08	Použitie magnézium-pyridoxal-5'-fosfátglutaminátu
Ramırez-Boscá et al.	2000	An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio: implications for atherogenesis prevention
de Sotillo et al.	2002	Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats
Bell et al.	1989	Cholesterol-lowering effects of psyllium hydrophilic mucilloid: adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia
Dujovne et al.	2002	Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
TW201900160A (zh)	2019-01-01	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
JP2004507498A (ja)	2004-03-11	高トリグリセリド血症治療用組成物及びその治療方法
Sekhar et al.	2005	Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome
OA11787A (en)	2005-07-26	Method for preventing or delaying catheter-based revascularization.
Ginsberg et al.	2001	Diabetes and dyslipidemia
Borhani	1985	Prevention of coronary heart disease in practice: implications of the results of recent clinical trials
Saravanan et al.	2006	Effect of a novel insulinotropic agent, succinic acid monoethyl ester, on lipids and lipoproteins levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes
Chin-Dusting et al.	2001	Lipids and atherosclerosis: clinical management of hypercholesterolaemia
Abdelwahab et al.	2025	Therapeutic benefits of Gum Arabic: Evidence from clinical trials
EP0568545A1 (de)	1993-11-10	Methode zur senkung erhöhter blutzuckerspiegel beim menschen
Hysenaj et al.	2024	IMPACT OF DYSLIPIDEMIA ON CORONARY HEART DISEASE IN WOMEN
Kh et al.	2025	THE ROLE OF OXIDATIVE STRESS AND DYSLIPIDAEMIA IN THE PATHOGENESIS OF CHRONIC PERIODONTITIS IN FATTY LIVER DISEASE
Razaaq	2021	An Physiological Enzymatic Study for Atherosclerosis Patients in the City of Fallujah
WO2013176564A1 (ru)	2013-11-28	Терпеноидное средство для профилактики и лечения атеросклероза и коррекции метаболического синдрома
Levy	1988	Currently available lipid-lowering agents
BROWN	1961	Idiopathic hyperlipemia and ischemic heart disease
Andryskowski et al.	2008	Effect of calcium lactate supplementation on cholesterol concentration in patients with hyperlipidaemia and previous viral hepatitis: a preliminary report: cardiovascular topics
Lee	2004	Fibrates in Perspective
Lorimer et al.	1985	Atherosclerosis and Hyperlipoproteinaemia
COLWELL et al.	2013	Antiplatelet Agents